Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06927947 · ClinicalTrials.gov registry record · NA
Navigation Interventions to Improve Cascade Genetic Testing Among Relatives of Patients With Hereditary Cancer Syndromes
A NA study of Hereditary Neoplastic Syndrome and Hereditary Malignant Neoplasm, sponsored by University of Michigan Rogel Cancer Center.
- Recruiting
- Registry status
- NA
- Development phase
- 500
- Enrollment target
- 1
- Study location
NCT06927947: Recruiting NA study of Hereditary Neoplastic Syndrome and Hereditary Malignant Neoplasm, sponsored by University of Michigan Rogel Cancer Center.
NCT06927947 is a NA study of Hereditary Neoplastic Syndrome and Hereditary Malignant Neoplasm that is actively recruiting participants, run by University of Michigan Rogel Cancer Center. The registered enrollment target is 500 participants, below the 9,850-participant average among 3 other Hereditary Neoplastic Syndrome trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06927947, a NA study of Hereditary Neoplastic Syndrome and Hereditary Malignant Neoplasm, is actively recruiting participants, sponsored by University of Michigan Rogel Cancer Center.
- RECRUITING
- Registry status
- NA
- Development phase
- 500 participants
- Enrollment target
- 1
- Study location
Study Summary
This clinical trial tests whether various web-based tools can help improve communication about hereditary cancer risk in families and decrease barriers to genetic testing for relatives of patients with hereditary cancer syndromes. Between 5% and 10% of all cancers are caused by genetic changes that are hereditary, which means that they run in families. Some kinds of cancer or certain cancers diagnosed in biological relatives may mean patients are more likely to have a genetic change. Once a genetic change is identified in a family, other biological relatives can choose to undergo testing themselves to better understand their cancer risk. The uptake of genetic testing in other biological relatives once a genetic condition is identified is about 20% to 30%. The Cascade Genetic Testing Platform is a virtual tool that seeks to overcome barriers related to logistics of family communication and improve dissemination of genetic testing information which is clinically actionable for individuals at highest risk for cancer. Using the Cascade Genetic Testing Platform may improve ways to share information about hereditary risk with biological relatives.
Primary Outcome
Will be defined as inviting at least 1 eligible at-risk relative. Will be assessed using descriptive statistics. Will be tabulated and summarized. Continuous variables will be summarized by mean, median, and standard deviation; histograms and boxplots will be used to further assess distributional characteristics of these variables. Categorical variables will be tabulated with frequencies and percentages. Will be estimated and presented along with a 95% confidence interval.
Conditions Studied
Interventions
- OTHER Survey Administration
- OTHER Communication Intervention
- OTHER Health Promotion and Education
- OTHER Informational Intervention
Study Locations (1)
Michigan
- University of Michigan Comprehensive Cancer Center - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2025-09-23 |
| Est. Completion | 2026-09-30 |
| Phase | NA |
What NCT06927947 shows while recruiting
NCT06927947 is an interventional study that assigns participants to a tested intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap, below the 9,850-participant average among 3 other Hereditary Neoplastic Syndrome trials with a reported enrollment target (95% lower).
The record links to 2 conditions, with Hereditary Neoplastic Syndrome appearing as the primary indexed condition, and to 4 interventions - of which Survey Administration is the first listed.
NCT06927947 reports a single indexed study location in Michigan.
Frequently Asked Questions
What is clinical trial NCT06927947 about?
NCT06927947 is a clinical study titled "Navigation Interventions to Improve Cascade Genetic Testing Among Relatives of Patients With Hereditary Cancer Syndromes". This clinical trial tests whether various web-based tools can help improve communication about hereditary cancer risk in families and decrease barriers to genetic testing for relatives of patients with hereditary cancer syndromes. Between 5% and 10% of all cancers are caused by genetic changes that ...
What is the current status of trial NCT06927947?
This trial is currently recruiting. It is a NA study. The enrollment target is 500 participants. The study started on 2025-09-23. Estimated completion is 2026-09-30.
What conditions does trial NCT06927947 study?
This clinical trial studies the following conditions: Hereditary Neoplastic Syndrome, Hereditary Malignant Neoplasm.
What interventions are being tested in trial NCT06927947?
The interventions under investigation include: Survey Administration (OTHER), Communication Intervention (OTHER), Health Promotion and Education (OTHER), Informational Intervention (OTHER).
Who is sponsoring clinical trial NCT06927947?
This trial is sponsored by University of Michigan Rogel Cancer Center, which has 292 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06927947 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hereditary Neoplastic Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001230 · 500 participants
Host Response to Infection and Treatment in Filarial Diseases
- NCT00001529 · 500 participants
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
- NCT00697411 · 500 participants
Study of Selected X-Linked Disorders: Aicardi Syndrome
- NCT00903110 · 500 participants
Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI